Lecanemab in Real-World Practice: What Early Alzheimer’s Patients Are Actually Experiencing Review Abstract Lecanemab represents a major milestone in the treatment of Alzheimer’s disease as the first anti amyloid monoclonal antibody to receive traditional approval from the United States Food and Drug Administration for patients with early
Tag: amyloid PET
